Actively Recruiting
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Led by Melbourne Health · Updated on 2025-02-28
100
Participants Needed
1
Research Sites
334 weeks
Total Duration
On this page
Sponsors
M
Melbourne Health
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
CONDITIONS
Official Title
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.
- Able to give informed consent.
You will not qualify if you...
- Unable to give informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Melbourne Health
Parkville, Victoria, Australia, 3050
Actively Recruiting
Research Team
M
Monica Slavin, Prof
CONTACT
T
Tseng Lau, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here